Dr Andrew Mark Thompson

BSc(Hons), PhD


I obtained my PhD in the field of marine natural products chemistry from the University of Canterbury, under the supervision of Drs John Blunt and Murray Munro. I joined the Auckland Cancer Society Research Centre in 1991 and, in partnership with Pfizer Global Research and Development, first investigated inhibitors of various kinases as novel anticancer therapies and then inhibitors of DNA gyrase as potential antibacterial agents. Since 2005, my research has focussed on the development of new drugs for tuberculosis and neglected tropical diseases, in collaboration with the Global Alliance for TB Drug Development and the Drugs for Neglected Diseases initiative. As Project Leader and chemist, I recently designed and synthesized DNDI-0690, a first-in-class drug candidate for visceral leishmaniasis which is now in clinical trials. I am currently an Associate Investigator in the Maurice Wilkins Centre for Molecular Biodiscovery.

Research interests

Research | Current

  • Design and synthesis of antitubercular drugs for nanoparticle and microparticle delivery

  • Target-based approaches to drug discovery for tuberculosis

  • Nitroheterocyclic compounds for the treatment of neglected diseases

Selected publications and creative works (Research Outputs)

  • Thompson, A. M., O'Connor PD, Marshall, A. J., Blaser, A., Yardley, V., Maes, L., ... Chatelain, E. (2018). Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of medicinal chemistry, 61 (6), 2329-2352. 10.1021/acs.jmedchem.7b01581
    URL: http://hdl.handle.net/2292/44743
    Other University of Auckland co-authors: Adrian Blaser, Bill Denny
  • Thompson, A. M., Marshall, A. J., Maes, L., Yarlett, N., Bacchi, C. J., Gaukel, E., ... Chatelain, E. (2018). Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic & medicinal chemistry letters, 28 (2), 207-213. 10.1016/j.bmcl.2017.10.067
    URL: http://hdl.handle.net/2292/42407
    Other University of Auckland co-authors: Bill Denny
  • Thompson, A. M., Bonnet, M., Lee, H. H., Franzblau, S. G., Wan, B., Wong, G. S., ... Denny, W. A. (2017). Antitubercular nitroimidazoles revisited: Synthesis and activity of the authentic 3-Nitro isomer of pretomanid. ACS Medicinal Chemistry Letters, 8 (12), 1275-1280. 10.1021/acsmedchemlett.7b00356
    URL: http://hdl.handle.net/2292/44558
    Other University of Auckland co-authors: Ho Lee, Bill Denny
  • Thompson, A. M., Blaser, A., Palmer, B. D., Anderson, R. F., Shinde, S. S., Launay, D., ... Wan, B. (2017). 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic and Medicinal Chemistry Letters, 27 (11), 2583-2589. 10.1016/j.bmcl.2017.03.069
    URL: http://hdl.handle.net/2292/34389
    Other University of Auckland co-authors: Brian Palmer, Adrian Blaser, Bob Anderson, Bill Denny
  • Thompson, A. M., O'Connor PD, Marshall, A. J., Yardley, V., Maes, L., Gupta, S., ... Franzblau, S. G. (2017). 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel antitubercular agents lead to a new preclinical candidate for visceral leishmaniasis. Journal of Medicinal Chemistry, 60 (10), 4212-4233. 10.1021/acs.jmedchem.7b00034
    URL: http://hdl.handle.net/2292/35110
    Other University of Auckland co-authors: Bill Denny
  • Satam, V. S., Pedada, S. R., Kamaraj, P., Antao, N., Singh, A., Hindupur, R. M., ... Martin, D. (2017). Development of a Scalable Process for the Synthesis of DNDI-VL-2098: A Potential Preclinical Drug Candidatefor the Treatment of Visceral Leishmaniasis. Organic Process Research and Development, 21 (1), 52-59. 10.1021/acs.oprd.6b00331
    URL: http://hdl.handle.net/2292/33077
  • Smaill, J., Gonzales, A., Spicer, J., Lee, H., Reed, J., Sexton, K., ... Blaser, A. (2016). Tyrosine kinase inhibitors. 20. optimization of substituted quinazoline and pyrido[3,4- d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family. Journal of Medicinal Chemistry, 59 (17), 8103-8124. 10.1021/acs.jmedchem.6b00883
    URL: http://hdl.handle.net/2292/32487
    Other University of Auckland co-authors: Jeffrey Smaill, Bill Denny, Julie Spicer, Brian Palmer, Adrian Blaser
  • O'Connor PD, Marshall, A. J., Denny, W. A., Yardley, V., Maes, L., Chatelain, E., & Thompson, A. M. (6/7/2016). Synthesis and SAR of 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines as novel antileishmanial agents. Poster presented at 52nd International Conference on Medicinal Chemistry, Caen, France.
    URL: http://hdl.handle.net/2292/41055
    Other University of Auckland co-authors: Bill Denny


Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 117
New Zealand

Web links